奥希替尼联合贝伐珠单抗在获得性EGFR T790M突变晚期非小细胞肺癌的疗效分析

BACKGROUND AND OBJECTIVE: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) capable of overcoming non-small cell lung cancer (NSCLC) with EGFR T790M mutation. Although the addition of bevacizumab to 1(st) generation EGFR-TKIs confers a signific...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2022
Materias:
临床研究
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845088/
https://www.ncbi.nlm.nih.gov/pubmed/36617470
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.56

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845088/
https://www.ncbi.nlm.nih.gov/pubmed/36617470
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.56

Ejemplares similares